RPRX — ROYALTY PHARMA PLC

Ownership history in Bayesian Capital Management, LP  ·  3 quarters on record

This page tracks every 13F SEC filing in which Bayesian Capital Management, LP reported a position in ROYALTY PHARMA PLC (RPRX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.36% (2025 Q3)
Avg. % of fund
0.2%
First filed
2021 Q2
Last filed
2025 Q3
Quarters held
3
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 ADDED 49,975 +34,723 +227.7% 0.36% $1.8M $34.90
2023 Q4 REDUCED 15,252 -4,048 -21.0% 0.05% $428K $26.44
2021 Q2 INITIATED 19,300 — — 0.21% $791K $36.62
% of Fund (quarterly)    RPRX price (monthly, adj. close)

Other funds also holding RPRX

As of 2025 Q4 — sorted by position size

Dorsey Asset Management, LLC 3Y 7Y 7.59% Regal Partners Ltd 3Y 7Y 5.88% Caledonia (Private) Investments Pty Ltd 3Y 7Y 5.46% NEW SOUTH CAPITAL MANAGEMENT INC 3Y 7Y 5.21% Patient Capital Management, LLC 3Y 4.97% Lion Point Capital, LP 3Y 7Y 4.28% TORRAY INVESTMENT PARTNERS LLC 3Y 7Y 4.12% Goodman Advisory Group, LLC 3Y 2.67% CM Management, LLC 3Y 2.44% Inlet Private Wealth, LLC 3Y 7Y 2.02%
← Back to Bayesian Capital Management, LP Holdings